Synonyms: GB-002 | Gb002 | PK-10571 | PK10571 | structure 2a [WO2014110200A1]
Compound class:
Synthetic organic
Comment: Seralutinib (PK10571; Structure 2a; GB002) is a small molecule inhibitor of platelet-derived growth factor receptors A and B (PDGFRα, PDGFRβ; receptor tyrosine kinases) [1]. It was developed to target the PDGF pathway as a therepuetic modality for the treatment of pulmonary arterial hypertension (PAH). PK10571 is being progressed for PAH by Gossamer Bio in collaboration with Pulmokine. Inhibition of PDGFRα/β is predicted to stop and/or reverse the vascular remodeling associated with PAH and thereby improve cardiopulmonary hemodynamics in these patients.
|
|
References |
1. Zisman LS. (2014)
Non-selective kinase inhibitors. Patent number: WO2014110200A1. Assignee: Zisman LS. Priority date: 10/01/2013. Publication date: 17/07/2014. |